Navigation Links
New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
Date:2/3/2011

e), STEPHEN NEAL (Cal State-Bakersfield), RICH OHRNBERGER (Penn State), QUINN OJINNAKA (Syracuse) and RYAN WENDELL (Fresno State).

"The offensive line doesn't always catch the fans' attention, so Prilosec OTC and I created this award to recognize the guys who provide the critical run blocking and pass protection," said John Madden.  "All season long, these guys proved they had the mental and physical toughness that enabled the Patriots offense to put up impressive numbers on the ground and in the air."

Throughout the regular season, Coach Madden closely tracked the top offensive lines in the NFL and narrowed the field of contenders to five (5) finalists: the ATLANTA FALCONS, KANSAS CITY CHIEFS, NEW ORLEANS SAINTS, NEW YORK GIANTS and the NEW ENGLAND PATRIOTS.  Each of the finalists had been recognized at least once this season by Madden as an "O-Line of the Week" for their consistent and reliable protection.

Contributing to their Madden Most Valuable Protectors Award win, the Patriots offensive line provided reliable run blocking and powerful pass protection for the top-ranked offense in the NFL. The Patriots led the league in points per game (32.4) and ranked 4th in sacks allowed (25). They finished 8th in average yards (363.8), ranked 9th in average rushing yards (123.3) and ranked 11th in passing yards per game (240.4).

Weighing 102 pounds, The Madden Most Valuable Protectors Award trophy is the heaviest trophy in NFL history and is a tribute to the NFL's toughest protectors on the offensive line.

NFL fans who want powerful can provide 24-hour protection against frequent heartburn(1), which is heartburn that occurs two or more days a week, can take a 14-day course of Prilosec OTC to maximize game day fun(2). Fans can go to www.PrilosecOTC.com for more information on the 14-day challen
'/>"/>

SOURCE Procter and Gamble
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pescatello Elected to Head New England Biotech Association in 2011-12
2. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
3. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
4. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
5. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
6. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
7. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
8. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
9. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
10. Whistleblower Lawyers Comment on New England Journal of Medicine Study
11. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Positive preclinical,data was presented by Nektar ... for its,lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which ... model of colorectal,cancer when co-administered with bevacizumab. ... (AACR) Annual Meeting 2008 in San Diego,California, ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
Cached Medicine Technology:Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 2Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 3Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 4Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 5Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... 2011 Studies show drinking V8 100% vegetable juice may be ... and may help them manage their weight two areas ... Guidelines for Americans. 1 A study conducted by ... drank one, 8-ounce glass of vegetable juice each day, as ...
... , THURSDAY, Feb. 3 (HealthDay News) -- Daily electronic ... doctors better understand the condition, a new study shows. ... digital assistant (PDA) device. The patients used their PDA ... issues three times a day for 30 days. ...
... DALLAS Feb. 3, 2011 UT Southwestern Medical ... a national network that conducts clinical trials aimed at ... 100 community treatment providers and academic medical centers throughout ... Institute on Drug Abuse,s Clinical Trials Network (CTN). The ...
... Feb. 2 (HealthDay News) -- Researchers report that DNA analysis ... rare vascular disease, along with its genetic cause. As ... England Journal of Medicine , the debilitating, painful and progressive ... the hands and feet of patients, and in the vascular ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... can help predict a daughter,s chances of not only having ... attack, new research shows. "Our new study shows that ... said Dr. Amitava Banerjee, a clinical research associate at the ...
... for ways to see dangerous blood clots before they ... School of Medicine in St. Louis report that they ... visible to a new kind of X-ray technology. ... cardiologist at Barnes-Jewish Hospital, these nanoparticles will take the ...
Cached Medicine News:Health News:Research suggests V8 100% vegetable juice can help people meet key dietary guidelines 2Health News:Researchers lead search for better drug-addiction treatments 2Health News:Scientists Discover Rare Vascular Disease 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: